IRF9 and acute lymphoblastic leukemia: In the B-ALL group D, the TFs STAT1, STAT2, and IRF9 exhibit significant activity in CD8+ TCM cells, where they can form the interferon-stimulated gene factor 3 (ISGF3) complex in response to type I interferon signaling [26], potentially enhancing anti-tumor immune surveillance.